Antibodies and Antibody Drug Conjugates (ADCs) conference
In-Person Event
Apr 09 - 10, 2018
London, England, GB
OVERVIEW
6th Annual Antibodies and Antibody Drug Conjugates (ADCs) conference is organized by SMi Group and will be held during Apr 09 - 10, 2018 at Copthorne Tara Hotel London Kensington, London, England, United Kingdom.
Conference Description :
Antibodies and antibody drug conjugates (ADCs) have the potential to make a groundbreaking impact upon medicinal therapies, diagnostics and characterization of diseases. There is massive potential for ADCs to be used in the development of targeted solid tumor therapies, due to their ability to act as precisely and effectively on target antigens.
Conference Objectives are :
• Presentations of clinical data from Phase I, II and III trials as case study examples of successes and short-falls of ADCs.
• Hear about cutting-edge combination therapies for onco-immunological therapies.
• Evaluating the latest regulatory updates and how they might affect the industry.
• Network with a range of industry and academic specialists and key vendors, from across the field.
Conference Highlights:
• Learn about the implementation of superior technologies to develop more effective and efficient Antibody Drug Conjugates.
• Discover new and novel payloads, e.g. Antibody Targeted Amanitin Conjugates (ATACs) and minorgroove binding DNA-interactive molecules as ADC payloads, to expand the ADC landscape.
• Discuss the practicalities of the use of Highly Potent Active Pharmaceutical Ingredients.
• Refine the practice of using fragment conjugates in order to develop a tailored therapy for solid tumours.
• Design principles for maximising the drug delivery efficiency and therapeutic index.
Additional details will be posted as soon as they are available.
Conference Description :
Antibodies and antibody drug conjugates (ADCs) have the potential to make a groundbreaking impact upon medicinal therapies, diagnostics and characterization of diseases. There is massive potential for ADCs to be used in the development of targeted solid tumor therapies, due to their ability to act as precisely and effectively on target antigens.
Conference Objectives are :
• Presentations of clinical data from Phase I, II and III trials as case study examples of successes and short-falls of ADCs.
• Hear about cutting-edge combination therapies for onco-immunological therapies.
• Evaluating the latest regulatory updates and how they might affect the industry.
• Network with a range of industry and academic specialists and key vendors, from across the field.
Conference Highlights:
• Learn about the implementation of superior technologies to develop more effective and efficient Antibody Drug Conjugates.
• Discover new and novel payloads, e.g. Antibody Targeted Amanitin Conjugates (ATACs) and minorgroove binding DNA-interactive molecules as ADC payloads, to expand the ADC landscape.
• Discuss the practicalities of the use of Highly Potent Active Pharmaceutical Ingredients.
• Refine the practice of using fragment conjugates in order to develop a tailored therapy for solid tumours.
• Design principles for maximising the drug delivery efficiency and therapeutic index.
Additional details will be posted as soon as they are available.
KEY DATES
09 Apr, 2018
Event Start Date
10 Apr, 2018
Event End Date
SPECIALITIES
Pharmacy and MedicineBiochemistry and Molecular GeneticsSUGGESTED HOTELS
CONFERENCE VENUE
Copthorne Tara Hotel London KensingtonRELATED CONFERENCES & LIVE WEBINARS
Quick Links